Abstract:Over the last few years, new generations of anti-CD20 monoclonal antibodies (mAbs) have been developed for potential benefits over the classical, first-generation mAb rituximab. Compared with rituximab, new mAbs have enhanced antitumor activity resulting from increased complement-dependent cytotoxicity (CDC) and/or antibody-dependent cellular cytotoxicity (ADCC) and increased Fc binding affinity for the low-affinity variants of the FcγRIIIa receptor (CD16) on immune effector cells. The second-generation mAbs, … Show more
“…Two such therapeutic antibodies, ofatumumab (Arzerra) and rituximab (Rituxan), were approved by the FDA in October 2009 and February 2010, respectively. Although these two agents, when used in combination with traditional chemotherapies, significantly increase survival for many patients (85), a substantial number of patients have disease that does not respond to initial treatment or eventually becomes resistant to it (85,86). As a result, researchers began working to develop more effective CD20-targeted therapeutic antibodies.…”
“…Currently there are more than ten agents targeting CD20, which are clinically approved or in clinical testing (originally reviewed in 43,44,29,35,45 and listed here in Table 1, which is compiled from these references, updated and modified). Accordantly, there are a number of published studies aiming to identify the molecular basis of the exerted clinical effects.…”
Section: Concluding ¨Per Analogiam¨ Is Not Possiblementioning
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.